Healthcare research – understanding the Chinese regulatory framework

Richard Tadd Blog

China has always been an attractive destination for researchers in the healthcare sector because of its size and population, and the scale of studies thus made possible. Until recently, though, its regulatory system was cumbersome and not well designed for foreigners, who found it hard to understand what was required of them. Thankfully, the past couple of years have seen …

The developing biotech sector in China

Richard Tadd Blog

Twenty years ago, China’s biotech industry was worth around $2.4bn. This year, its revenues are expected to exceed $1.2tn. That’s a remarkable achievement by any standards, and one that has understandably led to excitement among investors and industry professionals alike. How has it been achieved? How has the sector actually changed and what can we expect to see in the …

Growth and opportunity in Chinese biopharmaceutical markets staggering, say new reports

Richard Tadd Industry News

A report released in February by US-based Research and Markets addresses the shift in China away from low volume, high value manufacturing as a major catalyst for the increasing growth rate of China’s pharmaceutical market. The country now holds, at minimum, an 8 – 10% market share globally. The report goes on to state that greater technological advancements could quickly …

Promising Chinese Alzheimer’s drug to see $3bn investment over next 10 years

Richard Tadd Industry News

The Chinese pharmaceutical market sees another significant victory in recent weeks as it is announced that China has conditionally approved the first new Alzheimer’s drug to hit the global market in 17 years, and it will be distributed worldwide for long-term testing. The seaweed-derived drug GV-971, more colloquially known as Oligomannate, appears to improve cognition in patients with mild to …